Unpacking Key Data from ASH 2024 - Episode 5
Choosing Between Bispecifics and CAR T: Real-World Implications in R/R MM
Panelists discuss how the preliminary results from the iMMagine-1 trial on anitocabtagene autoleucel (ASH 2024, abstract #1031) inform the real-world decision-making between bispecifics and chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple myeloma (R/R MM).
Video content above is prompted by the following:
Choosing Between Bispecifics and CAR T in R/R MM
In real-world clinical decision-making, the choice between bispecific antibodies and CAR T therapy in R/R MM depends on multiple factors, including disease burden, treatment urgency, prior therapies, and patient eligibility. CAR T therapy offers the potential for deep, long-term remissions but requires bridging therapy and manufacturing time. Bispecific antibodies, available off the shelf, provide an alternative for patients needing rapid disease control or those ineligible for CAR T due to frailty or logistical constraints. Individualized treatment selection remains critical in optimizing outcomes for patients with R/R MM.
Related Content:
